New Millennium Group’s AstraZeneca AZN Stock Holding History

New Millennium Group’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$7.14K	Hold	39	–	–	﹤0.01%	224
2025 Q3	$5.96K	Sell	39 -201	-84%	-$30.4K	﹤0.01%	254
2025 Q2	$33.5K	Sell	240 -327	-58%	-$45.8K	0.02%	118
2025 Q1	$83.3K	Sell	567 -122	-18%	-$17.7K	0.05%	72
2024 Q4	$90.3K	Sell	689 -24	-3%	-$3.36K	0.05%	71
2024 Q3	$111K	Sell	713 -14,375	-95%	-$2.32M	0.07%	69
2024 Q2	$2.35M	Buy	+15,088	New	+$2.27M	1.54%	18
2024 Q1	–	Sell	-779	Closed	-$105K	–	95
2023 Q4	$105K	Sell	779 -201	-21%	-$26.1K	0.09%	74
2023 Q3	$133K	Sell	980 -18	-2%	-$2.46K	0.12%	49
2023 Q2	$143K	Sell	998 -298	-23%	-$43.8K	0.13%	52
2023 Q1	$180K	Sell	1,296 -6	-0.5%	-$807	0.18%	50
2022 Q4	$176K	Sell	1,302 -11	-0.8%	-$1.38K	0.19%	47
2022 Q3	$144K	Sell	1,313 -11	-0.8%	-$1.4K	0.16%	57
2022 Q2	$176K	Buy	+1,324	New	+$174K	0.18%	52

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

New Millennium Group's AZN Position: Q4 2025 in Review

New Millennium Group held its AstraZeneca (AZN) position steady in Q4 2025 at 39 shares worth $7.14K. The position accounts for ﹤0.01% of the portfolio, ranked #224.

New Millennium Group first reported a position in AZN in Q2 2022 and has held it in 14 quarters since. The position peaked at $2.35M in Q2 2024. 1,405 funds tracked by Wall St. Rank hold AZN as of Q4 2025.

New Millennium Group held 39 shares of AstraZeneca worth $7.14K as of Q4 2025.
New Millennium Group left its AstraZeneca share count unchanged in Q4 2025.
AstraZeneca made up ﹤0.01% of New Millennium Group's portfolio in Q4 2025, its #224 holding.
New Millennium Group first reported a position in AstraZeneca in Q2 2022 and has held it in 14 quarters since.
New Millennium Group's AstraZeneca position peaked at $2.35M in Q2 2024.
1,405 funds tracked by Wall St. Rank held AstraZeneca as of Q4 2025.

Based on New Millennium Group's 13F filing for Q4 2025, filed 6 Feb 2026.